Alkermes risk/reward favorable into FDA panel meeting, says Citi

Citi analyst Liav Abraham believes expectations heading into November’s FDA panel on Alkermes’ depression drug are low, implying a favorable risk-reward heading into the event. While key opinion leaders have expressed concerns around ALKS 5461’s “mixed” clinical data, they acknowledge the need for alternative therapeutic options in the adjunctive major depressive disorder space given, Abraham tells investors in a research note. The analyst sees reasons for the panel to vote either way ahead of the release of the briefing documents. She keeps a Buy rating on Alkermes.

https://thefly.com/landingPageNews.php?id=2793643